Advanced searches left 3/3

Carcinoid Syndrome - DOAJ

Summarized by Plex Scholar
Last Updated: 10 January 2023

* If you want to update the article please login/register

Carcinoid syndrome: update on the pathophysiology and treatment

Carcinoid syndrome, a paraneoplastic disorder related to a variety of genetic abnormalities, accounts for 30-40 percent of patients with well differentiated neuroendocrine tumors. As the first-line therapy, patients with neuroendocrine tumors and carcinoid syndrome have been treated with somatostatin analogues for many decades. More than 40 chemicals have been identified as potentially connected to carcinoid syndrome, but the individual contributions to various carcinoid signs or conditions, such as carcinoid heart disease, are uncertain.

Source link: https://doi.org/10.6061/clinics/2018/e490s


Carcinoid Syndrome-Induced Ventricular Tachycardia

Carcinoid tumors are rare neuroendocrine tumors that lack multiple bioactive substances, and they are very rare neuroendocrine tumors. Carcinoid syndrome associated with coronary vasospasm and the well-defined carcinoid heart disease have been described in previous case reports. Our patient, a 73-year-old female with a long medical history, is most notable for metastatic carcinoid tumors diagnosed in 2013-05. We hypothesize that the patient's ventricular tachycardia was mediated by a combination of bioactive chemicals that had been unveiled by her carcinoid tumors. parachycardia mediated by carcinoid syndrome and stifled by beta-blockers, to our knowledge.

Source link: https://doi.org/10.1155/2016/9142598


Endobronchial Carcinoid and Concurrent Carcinoid Syndrome in an Adolescent Female

Though the presence of carcinoid syndrome in a pediatric patient with an endobronchial carcinoid tumor has been found in a urine, palpitations, shortness of breath, and diarrhea, u2014 has been reported in association with adult bronchial carcinoid tumors, to our knowledge, only one new study has confirmed the presence of carcinoid syndrome. We provide a case of a 14-year-old girl with chronic cough who was found to have an endobronchial carcinoid tumor, as well as carcinoid syndrome.

Source link: https://doi.org/10.1155/2016/2074970


A Patient-Reported Outcomes Analysis Of Lanreotide In The Treatment Of NETs Patients With Carcinoid Syndrome: Evidence From The ELECT Trial

The aim of this review of patient-reported findings from the ELECT trial was to investigate the effect of lanreotide on carcinoid syndrome signs. Compared to placebo patients, Lanreotide patients were more likely to experience an increase on the C30-SS, diarrhea burden, and flushing burden than placebo patients. narcotide, patient-reported outcomes, neuroendocrine tumors, and flushing burden among diarrhea patients are among the three primary reasons for lanreotide therapy's use, according to the prevailing findings of a greater response rate in the quality-of-life domains, with the highest response rates in the diarrhea burden being identical with the previously reported effects of lanreotide treatment's emergence, as well as placebo patients. citations: NCT00774930 otide, otide octreoctreotide fibrotide-treated patients's, otide-otide's, otide vs, otide octreotide otide-otide-tide's's.

Source link: https://doaj.org/article/c350b08a9394413e8f35b4a05dbde481


Acute Inflammatory Bowel Disease Complicating Chronic Alcoholism and Mimicking Carcinoid Syndrome

Although carcinoid syndrome was hypothesized, abdominal computed tomography and colonoscopy revealed non-specific inflammatory bowel disease with severe colic wall thickening, and multiple colic biopsies confirmed non-specific inflammation with no signs of carcinoid cells. The patient was asymptomatic and serum potassium was normal one year after quinning from alcohol use. Hypotension during hospitalization can also be related to increased blood pressure, behavior problems, and anomalies in blood pressure control, as a result of hypothalamic-pituitary axis dysregulation. These, along with the relief of symptoms and normalization of potassium levels after reducing alcohol consumption, lead to the intriguing possibility of a alcohol-related acute inflammatory bowel disease similar to carcinoid syndrome.

Source link: https://doi.org/10.1159/000341588


Survival and Clinical Outcomes with Telotristat Ethyl in Patients with Carcinoid Syndrome

In patients with neuroendocrine tumors with telotristat ethyl in U. S. clinical practice, the TELEACE study found decreases in tumor size in patients with neuroendocrine tumors. Patients with the same pre- and post-telotristat ethyl background care received anonymized data for 200 patients; patients were treated with telotristat ethyl background treatment for a median of 9 months. At 6 and 12 months, the median time to tumor progression was 39. 8 months; the bulk had no tumor growth at 6 and 12 months. In the subgroup of 65 patients receiving the same pre/post background care, the results were consistent. Patients exhibited changes in cardiovascular symptoms, stable or elevated weight, and ECOG status following treatment with telotristat ethyl, according to previously reported tumor reductions. Keywords: neuroendocrine tumors, carcinoid syndrome, telotristat ethyl, and survival: In this exploratory pilot study, nearly all patients had improved carcinoid syndrome, autobioid syndrome, tethyroid syndrome, telotristat ethyl,.

Source link: https://doaj.org/article/d7857374dde9461692e6c99ac6d89cfd


Evaluation of meaningful change in bowel movement frequency for patients with carcinoid syndrome

Using data from the TELESTAR clinical study, this investigation was carried out to psychometrically evaluate significant change in bowel movement frequency among carcinoid syndrome patients. Methods An anchor-based strategy for deriving meaningful change thresholds consisted of mapping changes from baseline bowel movement frequency to other patient-reported assessments of change. Resulta 135 carcinoid syndrome patients had a mean baseline rate of 5. 7 bowel movements per day, according to the article. A day at Week 12, a distribution-based approach produced meaningful change estimates of 0. 62 bowel movements a day for total frequency and 0. 83 bowel movements. During the Double-blind Treatment Period and Week 12, Exit interview data for meaningful change yielded effect size estimates of u2212 1. 57 for overall change and u2212 1. 97 for change between Baseline and Week 12. 97 for significant change yielded effect size estimates of u2212 1. 57 for overall change and u2212 1. 97 for variation between Baseline and Week 12, which included meaningful change. Patients of carcinoid syndrome had statistically significant reductions in bowel movement frequency of u2265303 percent over 12 weeks with telotristat ethyl therapy, which was 45% in this study.

Source link: https://doi.org/10.1186/s41687-019-0153-y


Changes in Carcinoid Syndrome Symptoms Among Patients Receiving Telotristat Ethyl in US Clinical Practice: Findings from the TELEPRO-II Real-World Study

In clinical trials and observational studies, the safety of telotristat ethyl with a somatostatin analog for uncontrolled CS diarrhea has been shown. TELEPRO-II, a prospective observational study investigating TEu2019's effectiveness in clinical practice for the first three months of treatment, methods: Patients initiating TE in 2018 completed an optional nurse assistance service reporting CS symptoms during interviews at baseline, 1,2, and 3 months after TE implementation began. Patients with TE for u2265 3 months and reported symptom burden at baseline and a U22651-1 follow-up visit within the first three months. As events/episodes per day, daily bowel movement frequency and flushing episodes were reported as events/episodes per day. Results: A total of 684/1603 patients was eligible for analysis based on a cumulative distribution function, based on a decrease in daily BM frequency by 30 percent or u2265 30%. Patients at baseline reported a mean of 6. 3 BM/day, nausea severity of 8. 4/10, and stool urgency of 8. 2/10. After 3 months of TE, significant improvements in all CS symptoms were present. These patients also reported improvements in other conditions, leading to a u2265 percent decrease in daily BM frequency. Certainly, there have been improvements in CS symptoms for patients with a 30 percent decrease in daily BMs, chronic diarrhea, neuroendocrine tumor, and stool consistency, as well as nausea relief, somatostatin analog and TE.

Source link: https://doaj.org/article/44b265fb2dea4768a4187a5c79261daf


Developments in the treatment of carcinoid syndrome – impact of telotristat

Simron Singh Odette Cancer Centre, Sunnybrook Health Sciences Centre, Toronto, ON, Canada Abstract: Carcinoid syndrome is present in 20% of patients with neuroendocrine tumors, and serotonin is the most common causative hormonal peptide. Telotristat, a novel oral inhibitor of tryptophan hydroxylase, which is the rate-limiting enzyme in serotonin synthesis, is a novel oral inhibitor of tryptophan hydroxylase. A Phase III placebo-controlled trial of telotristat etiprate showed a significant decrease in the frequency of bowel motions in patients with diarrhea from carcinoid syndrome. Treatment with 500 mg three times a day reduced stool frequency, but it was associated with more nausea and mood disturbances than before. Telotristat, therefore, represents a viable option in the treatment of carcinoid syndrome diarrhea refractory to SSAs, and the U. S. Food and Drugs administration has approved the use of this term in March 2017. However, its role in somatostatin-na&'ve patients and other carcinoid syndrome disorders remains unclear.

Source link: https://doaj.org/article/e4db0365c8674cd68d80edc98f96683b


Update on Pathophysiology, Treatment, and Complications of Carcinoid Syndrome

When hormone levels reach a significant degree in the systemic circulation, Carcinoid syndrome develops in patients with hormone-producing neuroendocrine neoplasms. Chestcinoid syndrome has three typical signs: flushing, diarrhoea, abdominal pain, and wheezing are all typical signs. Serotonin overproduction can result in disease and tissue fibrosis formation, which can result in carcinoid syndrome-related disorders such as carcinoid heart disease and mesenteric fibrosis. fibrosis is one of the key contributing factors in fibrosis development, according to platelet-derived growth factor beta, basic fibroblast growth factor, and connective tissue growth factor. With somatostatin analogues, treatment of CS focuses on lowering serotonin levels. Despite being established on SSAu2019s, Telotristat ethyl and peptide receptor radionuclide therapy have recently become available to patients with symptoms.

Source link: https://doi.org/10.1155/2020/8341426

* Please keep in mind that all text is summarized by machine, we do not bear any responsibility, and you should always check original source before taking any actions

* Please keep in mind that all text is summarized by machine, we do not bear any responsibility, and you should always check original source before taking any actions